Stereotactic radiosurgery (SRS) for Glioblastoma

Phase-Based Progress Estimates
Stanford University, Stanford, CAGlioblastoma+1 MoreStereotactic radiosurgery (SRS) - Radiation
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new combination therapy for newly diagnosed glioblastoma (GBM). The safety and efficacy of the combination therapy of TTFields + SRS+ Temozolomide (TMZ) will be determined.

Eligible Conditions
  • Glioblastoma

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 30 months

1 month
Acute dose limiting toxicity
30 months
Overall Survival (OS)
5 months
Dose-limiting Toxicity (DLTs)
6 months
Progression-free Survival (PFS) at 6 Months

Trial Safety

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: Stereotactic radiosurgery (SRS) · No Placebo Group · Phase 1

Novo-TTFExperimental Group · 4 Interventions: Optune, Gadolinium, Stereotactic radiosurgery (SRS), Temozolomide · Intervention Types: Device, Drug, Radiation, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 30 months

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,186 Previous Clinical Trials
35,092,749 Total Patients Enrolled
3 Trials studying Glioblastoma
371 Patients Enrolled for Glioblastoma
NovoCure Ltd.Industry Sponsor
54 Previous Clinical Trials
4,504 Total Patients Enrolled
26 Trials studying Glioblastoma
2,606 Patients Enrolled for Glioblastoma
Scott G SoltysPrincipal InvestigatorStanford Universiy

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

What prior research has been done on the effectiveness of Stereotactic radiosurgery (SRS)?

"At present, 215 medical trials are underway exploring Stereotactic radiosurgery (SRS), with 23 of those in the third phase. While Seoul, Songpa is home to most investigations into this technique, there are 4777 other sites running studies regarding SRS across the globe." - Anonymous Online Contributor

Unverified Answer

Are any new participants eligible to join this research endeavor?

"Affirmative. Patients are currently being recruited for this clinical trial, details of which were initially posted on the 21st of May 2021 and recently updated on August 17th 2022." - Anonymous Online Contributor

Unverified Answer

To what maladies has Stereotactic radiosurgery (SRS) been clinically demonstrated to be efficacious?

"When dealing with nitrosourea treatment, advance directives and refractory advanced mycosis fungoides, Stereotactic Radiosurgery (SRS) can be employed as an efficacious therapeutic approach." - Anonymous Online Contributor

Unverified Answer

Has the government approved of Stereotactic Radiosurgery (SRS) for public use?

"SRS is still in its early stages of research, so it has been assigned a score of 1. This reflects the limited evidence available on this treatment's safety and efficacy." - Anonymous Online Contributor

Unverified Answer

What is the scale of enrollment for this research initiative?

"Affirmative. The clinical trial is still recruiting, as indicated on its page hosted on It was initially posted on May 21st 2021 and the last update was August 17th 2022; 12 volunteers are being sought out from a single medical centre." - Anonymous Online Contributor

Unverified Answer

Is this research endeavor pioneering in its approach?

"Globally, there are 36 countries with 940 cities encompassing 215 active clinical trials regarding Stereotactic Radiosurgery (SRS). The first trial of its kind was conducted in 2002 by Schering-Plough. This study featured 60 patients and achieved Phase 2 drug approval. Since then, 315 more studies have been completed." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.